The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Enliven Therapeutics Inc shares valued at $84,550 were purchased by Kintz Samuel on Dec 17 ’25. At $16.91 per share, Kintz Samuel acquired 5,000 shares.
Also, Patel Anish sold 6,663 shares, netting a total of over 140,073 in proceeds. Following the sale of shares at $21.02 each, the insider now holds 263,311 shares.
Before that, Patel Anish had added 6,663 shares to its account. In a trade valued at $145,320, the Officer bought Enliven Therapeutics Inc shares for $21.81 each.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] rose 4.12% to $16.68. The stock’s lowest price that day was $15.7701, but it reached a high of $16.9 in the same session. During the last five days, there has been a drop of approximately -11.13%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -29.23%. Shares of the company reached a 52-week high of $25.37 on 01/03/25 and a 52-week low of $13.30 on 04/10/25.
Support And Resistance Levels for Enliven Therapeutics Inc (ELVN)
According to the 24-hour chart, there is a support level at 16.00, which, if violated, would cause prices to drop to 15.32. In the upper region, resistance lies at 17.13. The next price resistance is at 17.58. RSI (Relative Strength Index) is 35.65 on the 14-day chart, showing neutral technical sentiment.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.21 million shares to 8.0 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 7.78 million shares. A jump of 2.68% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.8 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.8.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 39 in the next 12 months, up nearly 143.45% from the previous closing price of $16.02. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2025, with the lowest price target being 39. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2025. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
